Severe septicaemia in a patient with polychondritis and Sweet's syndrome after initiation of treatment with infliximab.
Matzkies
F G
FG
University of Erlangen-Nuremberg, Department of Internal Medicine III and Institute for Clinical Immunology, Krankenhausstrasse 12, 91054 Erlangen, Germany.
Manger
B
B
Schmitt-Haendle
M
M
Nagel
T
T
Kraetsch
H-G
HG
Kalden
J R
JR
Schulze-Koops
H
H
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D003922:Diabetes Mellitus, Type 1 / Q000150:complications / Q000276:immunology; D017809:Fatal Outcome; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D011081:Polychondritis, Relapsing / Q000150:complications* / Q000276:immunology; D018805:Sepsis / Q000209:etiology* / Q000276:immunology; D016463:Sweet Syndrome / Q000150:complications* / Q000276:immunology
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D000069285:Infliximab; D001379:Azathioprine